Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771407 | 0.94 | ITK (0.88) | ITK | |
| SCHEMBL6632543 | 0.92 | ITK (1.00) | ITK | |
| SCHEMBL6766640 | 0.90 | ITK (0.92) | ITK | |
| SCHEMBL6770839 | 0.89 | ITK (0.82) | ITK | |
| SCHEMBL6771435 | 0.89 | ITK (0.82) | ITK | |
| SCHEMBL14586355 | 0.79 | ITK (1.00) | ITK | |
| Thiophene SCHEMBL27614397 | 0.79 | ITK (0.65) | ITK | |
| SCHEMBL6632540 | 0.76 | ITK (0.72) | ITK | |
| SCHEMBL6772813 | 0.76 | ITK (0.69) | ITK | |
| SCHEMBL6635249 | 0.72 | ITK (0.64) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825219-B2 | NITROGEN COMPOUNDS SUCH AS 4-((5-(CYCLOHEXYL-METHYL-CARBAMOYL) -2(THIOPHENE-2-CARBONYL)-AMINO)BENZIMIDAZOL-1-YL)-BUTYRIC ACID ADMINISTERED FOR THE PROPHYLAXIS OF INFLAMMATORY, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030144281-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144281-A1 | Substituted benzimidazole compounds | HRH2, HRH4, HRH1 | ITK 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.